Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-07-20
EX-99.1
This press release provides a business update on Organigram's operational performance following its April 2026 acquisition of Sanity Group GmbH, including Sanity's market share in Germany (~10%), Canadian market share metrics across key categories (flower, vapes, pre-rolls), and sequential improvements in Q2 FY2026. While the disclosure includes forward-looking guidance on Q3 reporting and an investor session, the core substance is an operational update on post-acquisition integration and market positioning rather than a discrete event (M&A completion already occurred in April) or periodic financial results. The material market share data and performance metrics would affect a reasonable investor's assessment of the company's competitive position and acquisition success.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-07-20
Item 1.01
Gap Inc. entered into Amendment No. 2 to its Fourth Amended and Restated Revolving Credit Agreement on July 17, 2026, extending the maturity of its $2.2 billion asset-based lending facility from July 2027 to July 2031 and modifying key terms including interest rates and covenants.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-07-20
This is Ryanair's Q1 FY27 earnings announcement, disclosing quarterly financial results for the period ended June 30, 2026. The document presents a comprehensive earnings release with headline PAT of €538m (down 34% year-over-year), detailed income statement, balance sheet, cash flow statement, and management discussion. The disclosure is material as it reports significant financial results and operational metrics that would affect investor assessment of the company's performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-20
Item 2.02
Peoples Bancorp of North Carolina disclosed second quarter 2026 earnings results via press release furnished as Exhibit 99(a), materially affecting investor assessment of the company's financial performance and condition.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-20
GSK announced that the European Medicines Agency (EMA) has accepted a submission to update the Bexsero label to include a single-dose booster for individuals aged 10+ who were previously vaccinated. This is a material regulatory milestone for a key product (Bexsero, with 138 million doses distributed globally since 2015) that could expand its market application and clinical utility. While not a discrete M&A, financial, or governance event, this represents a significant operational and commercial development in product development and regulatory approval pathway.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 15%
filed 2026-07-20
This is a major holdings notification (TR-1 form) disclosing that The Capital Group Companies, Inc. and Capital Research and Management Company crossed above the 17.00% voting threshold in Ryanair Holdings PLC on 16 July 2026, increasing from 16.08% to 17.03%. This is a material change in share ownership structure that would affect investor assessment of control and influence.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-20
Item 5.03
This disclosure reports a reverse stock split (1-for-3) of TOMI Environmental Solutions' common and preferred stock, approved by shareholders on June 4, 2026, and effective July 20, 2026. While a reverse stock split is a structural capital event, it is fundamentally a governance and corporate action matter—an amendment to the articles of incorporation affecting share structure—rather than a financial obligation, operational change, or material impairment. The event is material to investors because it affects share count, trading mechanics, and the company's market presentation, but it fits best within governance_other as a non-routine amendment to capitalization structure that does not fit the specific named governance categories (exec_departure, exec_appointment, exec_compensation, shareholder_vote_results).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
The filing discloses an unregistered sale of 4,805,778 Class L common shares for $70 million on July 1, 2026, made pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors and qualified purchasers. This is a classic dilutive private placement of equity securities that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-20
Item 1.01
OXO entered into a 36-month Commercial Reseller Agreement with Cegeka NV granting non-exclusive rights to market and resell subscriptions for the Company's MMM Neural platform, with aggregate commercial commitments of approximately $450,000. This is a material commercial partnership that does not fit the specific M&A categories (no acquisition, merger, or change of control), but represents a significant operational and strategic business arrangement that would affect investor assessment of the company's revenue and market reach.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-20
Item 4.01
The filing discloses a change in the registrant's independent registered public accounting firm, with Elkana Amitai, CPA replaced by Vilki & Co effective July 1st, 2026. This is a classic auditor change under Item 4.01(a), and the company explicitly states there were no disagreements with the former auditor and no reportable events, which is the standard disclosure format for such changes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 1.01
Sunshine Biopharma entered into an At-The-Market (ATM) Issuance Sales Agreement on July 20, 2026, authorizing the sale of up to $4,000,000 in common stock shares through Aegis Capital Corp. ATM offerings are unregistered equity issuances that create dilution to existing shareholders and are a material capital-raising mechanism, particularly for smaller biotech companies. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), confirming materiality.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-20
Item 8.01
The Company disclosed receipt of a Nasdaq deficiency notification for failure to timely file its Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). While the Company submitted a Compliance Plan and trading continues, the filing directly addresses a material delisting risk — the Company faces potential delisting if the Compliance Plan is rejected and it cannot regain compliance. This is a core delisting-risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
Monroe Capital Income Plus Corp issued 1,145,836 shares of common stock at $9.77 per share for an aggregate offering price of $11.2 million pursuant to subscription agreements, with the sale exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-20
Item 8.01
The board declared a dividend distribution of $0.068 per share to stockholders of record as of July 21, 2026, payable on or about July 29, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-07-20
Item 3.01
SES AI received notice from the NYSE on July 17, 2026, that it failed to comply with Section 802.01C of the NYSE Listed Company Manual because the average closing price of its Class A common stock was below $1.00 over a consecutive 30 trading-day period. The company has a six-month cure period to regain compliance or face potential delisting.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-20
EX-99.1
VERAXA announced receipt of Scientific Advice from the German regulatory authority (Paul-Ehrlich-Institute) supporting the biological rationale and proposed development approach for its BiTAC-TCE technology platform. This is a material regulatory milestone that de-risks the development path for the company's most-advanced program and provides clarity on the regulatory pathway forward. While not a discrete event type like exec_appointment or debt_issuance, this regulatory validation is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's progress toward clinical development.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-20
Item 7.01
FinWise Bancorp announced the completion of an acquisition of Tallied Technologies, Inc.'s technology platform and related assets on July 20, 2026. The press release explicitly states "FinWise Bancorp Acquires Tallied Technology Platform" and describes this as a strategic acquisition that brings credit card issuing and processing in-house, expands revenue capture, and adds approximately $50 million in credit card receivables to the balance sheet. This is a material acquisition of a technology platform and business assets that materially affects the company's operations and financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
The Company sold 1,677,806 unregistered shares of common stock for approximately $33.4 million pursuant to subscription agreements with investors, exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-20
Item 7.01
The Board of Directors declared a regular monthly distribution of $0.167 per share payable on August 27, 2026, consistent with the company's regular monthly distribution policy.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-20
Item 8.01
The Company disclosed quarterly net asset value of $19.92 per share, net investment income of $0.57 per share, and portfolio metrics as of June 30, 2026, along with the status of an ongoing private offering ($2.891 billion issued to date toward a $4.5 billion target).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-20
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 2,139,619 shares of Class I common shares to feeder vehicles for approximately $22.9 million in gross proceeds, with the offering exempt from registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-07-20
Item 8.01
The Company disclosed its Net Asset Value (NAV) per share as of June 30, 2026, broken down by share class (S, N, D, I), along with a detailed portfolio update showing 3,927 properties, total portfolio assets of $12.6 billion, and key metrics including weighted average lease terms and debt ratios.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-20
Item 5.02
The filing discloses the appointment of Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026, replacing Mary Wilcox. While the disclosure includes compensatory details (base salary, bonus, equity grants, sign-on bonus), the principal action is the appointment of an officer to a key accounting and financial reporting role. The appointment of a Principal Accounting Officer for SEC reporting purposes is material to investors' assessment of the company's financial controls and governance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-20
Item 8.01
The filing discloses a Board declaration of a dividend distribution of $0.187 per Class I Share to be paid in cash on or about August 24, 2026. This is a routine but material dividend declaration by a closed-end fund, which is a standard capital distribution to shareholders. The Item 8.01 disclosure of the dividend, combined with the supporting net asset value and portfolio information, clearly indicates a dividend_distribution event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
Blue Owl Digital Infrastructure Trust sold 12,470,870 common shares for approximately $131.7 million in gross proceeds on July 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-20
Item 8.01
The company declared and paid distributions to shareholders across four classes of common shares (Class S, D, I, and E) on June 29, 2026, with net distributions ranging from $0.0344591 to $0.0416667 per share, paid on or about July 17, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-17
Item 2.02
Fifth Third Bancorp issued a press release on July 17, 2026 announcing its second quarter 2026 earnings results, disclosing net income available to common shareholders of $763 million ($0.83 diluted EPS) and key financial metrics including net interest income, noninterest income, and noninterest expense.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-17
Item 2.02
FNB Corporation disclosed quarterly financial results for Q2 2026 via press release attached as Exhibit 99.1, reporting net income of $148.7 million ($0.42 per diluted share), record revenue of $462.7 million, and 16.7% year-over-year EPS growth. This is a standard earnings release disclosure under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-17
Item 5.02
Rayonier announced the permanent appointment of Ryan M. Daniels as Senior Vice President, Wood Products, effective immediately, converting his interim role (held since March 2026) to a permanent position. The Board approved the appointment on July 16, 2026, with a compensation package including $450,000 base salary, 65% cash bonus eligibility, and severance plan participation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-17
Item 2.02
The Company issued a press release on July 17, 2026 announcing second quarter and year-to-date 2026 financial results, including net income of $2.208 billion ($10.26 per diluted share) for Q2 2026 and core income of $2.160 billion ($10.04 per diluted share). The disclosure includes detailed consolidated and segment financial metrics, combined ratios, underwriting performance, and capital allocation activities. This is a standard quarterly earnings release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-17
Item 2.02
Truist Financial Corporation disclosed its second quarter 2026 financial results via press release on July 17, 2026, reporting net income available to common shareholders of $1.5 billion, diluted EPS of $1.23 (up 37% year-over-year), and key performance metrics including ROCE of 10.4% and ROTCE of 15.4%. The filing includes the Earnings Release, Quarterly Performance Summary, and Earnings Release Presentation as exhibits, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-17
Item 2.02
WaFd, Inc. announced quarterly earnings for the quarter ended June 30, 2026 via press release on July 16, 2026, disclosing net income of $66.1 million and diluted earnings per share of $0.84. The filing explicitly states this information is being furnished under Item 2.02 (Results of Operations and Financial Condition), with the press release attached as Exhibit 99.1 containing detailed financial results, balance sheet data, and performance metrics.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-17
Item 1.01
Uniti Group completed a private offering of $1,140,710,000 aggregate principal amount of secured fiber network revenue term notes on July 15, 2026, consisting of three classes (A-2, B, and C) with varying interest rates and a June 2033 anticipated repayment date. This represents a material capital-raising transaction for the company's fiber-to-the-home securitization program.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-17
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on July 16, 2026, where shareholders voted on three proposals, including approval of a merger agreement with KL Criss Cross Intermediate, LLC. Proposal 1 (the Merger Agreement Proposal) was approved with 23,356,105 votes in favor versus 12,309 against, and Proposal 2 (Advisory Merger-Related Compensation) was also approved. This is a classic shareholder vote results disclosure that is material because it confirms stockholder approval of a transformative merger that will result in the company being delisted from NASDAQ and deregistered under the Securities Exchange Act.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-17
Item 5.02
Jill Larsen was appointed to OpenText's board of directors effective immediately on July 17, 2026. Larsen is a seasoned executive with extensive HR and organizational leadership experience at major technology companies including Synopsys, Cisco, EMC, and PTC. The appointment was announced concurrently with the resignation of director Kristen Ludgate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-17
Item 8.01
The disclosure announces a four-unit RIO 360 order from a high-profile pop culture brand customer through AITX's dealer channel. This is a material operational/commercial event demonstrating product adoption and dealer channel effectiveness, but does not fit the specific taxonomy categories (not earnings, M&A, impairment, litigation, etc.). The company explicitly notes this order "illustrates the effectiveness of its dealer channel strategy" and represents "commercial momentum," making it material to investors assessing the company's operational performance and market traction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-17
Item 1.01
Kimbell Royalty Partners entered into a Purchase and Sale Agreement on July 16, 2026, to acquire mineral interests, royalty interests, and partnership interests in oil and gas properties for approximately $215.4 million in total consideration ($74.9 million cash plus 9.5 million newly issued units representing 2,568 net royalty acres across premier basins). The transaction is expected to close on August 21, 2026, and is immediately accretive to distributable cash flow per unit.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-17
EX-99.1
Nebius announced entry into its first senior secured debt facility for approximately $775 million, backed by GPU infrastructure and contracted cash flows, maturing October 31, 2030, and priced at SOFR + 2.50%. This is a material creation of a direct financial obligation that would affect a reasonable investor's assessment of the company's capital structure and financing strategy.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-17
Sony announced the disposal of 1,142,196 treasury shares upon vesting of restricted stock units (RSUs) granted to directors, officers, and employees under its stock compensation plan. The announcement details the vesting mechanics, allottees (including 1 director and 1 corporate executive officer of the Corporation), and the total disposal price of approximately 3.9 billion yen. This is a material disclosure of compensatory arrangements involving equity grants and their settlement, falling squarely within exec_compensation rather than a routine administrative matter.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-17
EX-99.1
Vision Marine Technologies announced unaudited financial results for the three-month and nine-month periods ended May 31, 2026, reporting Q3 revenue of $18.4 million (27% sequential growth), nine-month revenue of $48.6 million, gross profit of $11.8 million at 24.3% margin, and a net loss of $11.9 million.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-17
EX-99.2
Vision Marine completed an at-the-market (ATM) equity offering program that raised approximately US$16.3 million in gross proceeds through the issuance of 6,380,235 common shares, bringing total outstanding shares to 6,530,460.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-17
EX-99.1
This announcement discloses the grant of 16,220,972 restricted share units (RSUs) to 438 employees under the 2026 Share Incentive Plan on July 17, 2026, representing approximately 0.36% of total issued shares. The disclosure details vesting schedules, performance conditions, clawback mechanisms, and the rationale for the grants—all hallmarks of executive and employee compensation arrangements. While the grantees are not named executives, the scale and structure of this equity grant constitute a material compensatory arrangement requiring disclosure under Hong Kong Listing Rules 17.06A–C.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-17
Item 1.01
Csquare completed its initial public offering on July 17, 2026, selling 50 million shares at $21.00 per share for net proceeds of $1,010 million under an underwriting agreement with Morgan Stanley and TD Securities. The IPO included concurrent entry into registration rights and stockholders agreements with Brookfield, granting board nomination rights and significant governance protections, representing a material change of control and capital structure event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-07-17
Item 5.03
Transcode Therapeutics amended the Certificate of Designation for Series C Preferred Stock, increasing the beneficial ownership limitation from 4.99% to 9.99% and correcting scrivener's errors. The amendment was approved by the Board and Series C holders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-17
Item 1.01
IPG Photonics entered into a binding Put Option Agreement on July 16, 2026, to acquire 100% of Lumibird Medical for €300 million plus up to €50 million in contingent earnout consideration on a cash-free, debt-free basis, with expected closing in Q4 2026. The acquisition is expected to expand IPG's Advanced Solutions portfolio, create a scaled medical laser platform, and be accretive to gross margin, EBITDA, and adjusted EPS.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-17
Item 1.01
The filing discloses an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., extending the Outside Date from July 17, 2026 to July 21, 2026. This is a material modification to an existing M&A transaction that would affect a reasonable investor's assessment of the deal's status and timeline.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-17
Item 2.02
South Plains Financial issued a press release on July 17, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $19.0 million, diluted EPS of $0.96, and other key financial metrics.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-17
Item 8.01
South Plains Financial declared a quarterly cash dividend of $0.18 per share on outstanding common stock, payable August 10, 2026 to shareholders of record as of July 27, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-17
EX-99.1
This press release announces Evaxion's presentation of three-year clinical efficacy data for its lead cancer vaccine candidate EVX-01 at the ESMO Congress 2026. The disclosure highlights positive trial results (75% ORR, 92% durability at two years, and new stand-alone therapy data) that are material to investors assessing the company's clinical progress and commercial prospects. While not a discrete event like an approval or M&A transaction, the announcement of significant clinical milestone data from an ongoing phase 2 trial is a material operational/clinical development event that would affect a reasonable investor's assessment of the registrant's pipeline and competitive position.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-17
The 6-K discloses an ongoing shareholder activism campaign initiated by shareholders who filed a Schedule 13D on July 10, 2026, demanding removal of all current board members except the CEO and replacement with activist nominees. While the filing also mentions an increase in an at-the-market offering amount, the substantive disclosure is the risk factors update addressing the material governance threat posed by the activist campaign, including potential proxy contests, board composition changes, and operational disruption. This is a governance event—specifically shareholder activism and potential proxy contest risk—that does not fit the specific categories of exec_departure, exec_appointment, or shareholder_vote_results (no vote has occurred yet), making governance_other the appropriate classification.
View raw filing on EDGAR →